Exome Asset Management
Latest statistics and disclosures from Exome Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, COGT, GH, IONS, LLY, and represent 26.62% of Exome Asset Management's stock portfolio.
- Added to shares of these 10 stocks: WVE (+$7.2M), ELV (+$6.0M), JAZZ, AGIO, ELVN, CELC, APLS, DXCM, VSTM, Travere Therapeutics.
- Started 26 new stock positions in CELC, Ultragenyx Pharmaceutical In, JAZZ, VSTM, UNH, IKT, KPTI, Disc Medicine, DXCM, Soleno Therapeutics.
- Reduced shares in these 10 stocks: PRAX (-$13M), COGT, ETNB, BBIO, APGE, NBP, ARWR, CVS, SLNO, AKRO.
- Sold out of its positions in ATYR, ACAD, AKRO, COR, APGE, Arcturus Therapeutics Hldg I put, AVTX, CVS, CNTA, Centessa Pharmaceuticals.
- Exome Asset Management was a net seller of stock by $-25M.
- Exome Asset Management has $209M in assets under management (AUM), dropping by 26.64%.
- Central Index Key (CIK): 0002011932
Tip: Access up to 7 years of quarterly data
Positions held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Exome Asset Management
Exome Asset Management holds 60 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 8.2 | $17M | -43% | 58k | 294.74 |
|
| Cogent Biosciences (COGT) | 5.2 | $11M | -31% | 306k | 35.52 |
|
| Guardant Health (GH) | 4.8 | $10M | 98k | 102.14 |
|
|
| Ionis Pharmaceuticals (IONS) | 4.4 | $9.2M | -11% | 117k | 79.11 |
|
| Eli Lilly & Co. (LLY) | 4.0 | $8.4M | 7.9k | 1074.68 |
|
|
| Cytokinetics Com New (CYTK) | 3.8 | $7.9M | -12% | 125k | 63.54 |
|
| Wave Life Sciences SHS (WVE) | 3.4 | $7.2M | NEW | 422k | 17.00 |
|
| Vera Therapeutics Cl A (VERA) | 3.0 | $6.3M | -20% | 124k | 50.64 |
|
| Bridgebio Pharma (BBIO) | 3.0 | $6.2M | -39% | 81k | 76.49 |
|
| Anthem (ELV) | 2.9 | $6.0M | NEW | 17k | 350.55 |
|
| Astrazeneca Sponsored Adr | 2.5 | $5.3M | 28k | 185.48 |
|
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.2 | $4.5M | NEW | 27k | 170.00 |
|
| Natera (NTRA) | 2.0 | $4.3M | 19k | 229.09 |
|
|
| Immunovant (IMVT) | 1.9 | $4.0M | 159k | 25.42 |
|
|
| Universal Hlth Svcs CL B (UHS) | 1.8 | $3.8M | +121% | 18k | 218.02 |
|
| United Therapeutics Corporation (UTHR) | 1.8 | $3.7M | +15% | 7.7k | 487.25 |
|
| Agios Pharmaceuticals (AGIO) | 1.8 | $3.7M | NEW | 137k | 27.22 |
|
| Disc Medicine (IRON) | 1.8 | $3.7M | -23% | 47k | 79.41 |
|
| Intuitive Surgical Com New (ISRG) | 1.7 | $3.6M | 6.4k | 566.36 |
|
|
| Glaukos (GKOS) | 1.7 | $3.6M | +15% | 32k | 112.91 |
|
| Enliven Therapeutics (ELVN) | 1.6 | $3.4M | NEW | 222k | 15.40 |
|
| Celcuity (CELC) | 1.6 | $3.4M | NEW | 34k | 99.74 |
|
| Apellis Pharmaceuticals (APLS) | 1.6 | $3.4M | NEW | 136k | 25.12 |
|
| Travere Therapeutics (TVTX) | 1.6 | $3.4M | -43% | 89k | 38.21 |
|
| Dex (DXCM) | 1.6 | $3.3M | NEW | 50k | 66.37 |
|
| Arrowhead Pharmaceuticals (ARWR) | 1.6 | $3.3M | -52% | 50k | 66.39 |
|
| Cytomx Therapeutics (CTMX) | 1.5 | $3.2M | 745k | 4.26 |
|
|
| Liquidia Corporation Com New (LQDA) | 1.5 | $3.1M | -3% | 91k | 34.49 |
|
| Verastem Com New (VSTM) | 1.5 | $3.1M | NEW | 402k | 7.72 |
|
| Travere Therapeutics Put Put Option | 1.4 | $2.9M | NEW | 75k | 38.21 |
|
| Alumis (ALMS) | 1.4 | $2.9M | 292k | 9.76 |
|
|
| Penumbra (PEN) | 1.3 | $2.8M | 9.0k | 310.91 |
|
|
| 10x Genomics Cl A Com (TXG) | 1.3 | $2.7M | 164k | 16.31 |
|
|
| Immunocore Hldgs Ads (IMCR) | 1.3 | $2.7M | NEW | 77k | 34.71 |
|
| Edgewise Therapeutics (EWTX) | 1.2 | $2.5M | -42% | 100k | 24.82 |
|
| Nextcure Com New (NXTC) | 1.1 | $2.3M | NEW | 165k | 14.19 |
|
| Belite Bio Sponsored Ads (BLTE) | 1.1 | $2.3M | NEW | 14k | 159.96 |
|
| Waystar Holding Corp (WAY) | 1.1 | $2.3M | +47% | 69k | 32.75 |
|
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 1.0 | $2.2M | NEW | 649k | 3.37 |
|
| Karyopharm Therapeutics Com New (KPTI) | 1.0 | $2.2M | NEW | 296k | 7.36 |
|
| Adagene Ads (ADAG) | 1.0 | $2.0M | NEW | 1.1M | 1.89 |
|
| Novabridge Biosciences Sponsored Ads (NBP) | 1.0 | $2.0M | -65% | 500k | 3.98 |
|
| UnitedHealth (UNH) | 0.9 | $1.9M | NEW | 5.8k | 330.11 |
|
| Palisade Bio (PALI) | 0.9 | $1.8M | NEW | 758k | 2.35 |
|
| Upstream Bio (UPB) | 0.8 | $1.8M | +24% | 65k | 27.15 |
|
| Gossamer Bio (GOSS) | 0.7 | $1.4M | 452k | 3.10 |
|
|
| Disc Medicine Put Put Option | 0.6 | $1.3M | NEW | 16k | 79.41 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.6 | $1.2M | NEW | 600k | 2.05 |
|
| Iqvia Holdings (IQV) | 0.6 | $1.2M | NEW | 5.4k | 225.41 |
|
| Tenet Healthcare Corp Com New (THC) | 0.6 | $1.2M | -66% | 6.1k | 198.72 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.5 | $1.1M | -39% | 140k | 8.14 |
|
| Fulcrum Therapeutics (FULC) | 0.5 | $1.0M | -6% | 92k | 11.31 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.5 | $955k | 13k | 72.88 |
|
|
| Ultragenyx Pharmaceutical In Put Call Option | 0.4 | $810k | NEW | 35k | 23.00 |
|
| Alumis Put Put Option | 0.2 | $519k | NEW | 53k | 9.76 |
|
| Aldeyra Therapeutics Call Call Option | 0.2 | $518k | NEW | 100k | 5.18 |
|
| Rapt Therapeutics Com New (RAPT) | 0.2 | $481k | NEW | 14k | 33.87 |
|
| Precigen Put Put Option | 0.2 | $418k | 100k | 4.18 |
|
|
| Arbutus Biopharma (ABUS) | 0.2 | $363k | 76k | 4.81 |
|
|
| Soleno Therapeutics Put Put Option | 0.2 | $328k | NEW | 7.1k | 46.13 |
|
Past Filings by Exome Asset Management
SEC 13F filings are viewable for Exome Asset Management going back to 2023
- Exome Asset Management 2025 Q4 filed Feb. 13, 2026
- Exome Asset Management 2025 Q3 filed Nov. 14, 2025
- Exome Asset Management 2025 Q2 restated filed Aug. 15, 2025
- Exome Asset Management 2025 Q1 restated filed May 16, 2025
- Exome Asset Management 2025 Q1 filed May 15, 2025
- Exome Asset Management 2024 Q4 filed Feb. 14, 2025
- Exome Asset Management 2024 Q3 amended filed Dec. 13, 2024
- Exome Asset Management 2024 Q2 restated filed Oct. 3, 2024
- Exome Asset Management 2024 Q2 filed Aug. 14, 2024
- Exome Asset Management 2024 Q1 filed May 15, 2024
- Exome Asset Management 2023 Q4 filed Feb. 15, 2024